Quantcast

Latest Reverse transcriptase inhibitor Stories

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

Researcher Finds Soy Sauce Molecule May Unlock Drug Therapy For HIV Patients
2014-05-05 03:45:36

Jeff Sossamon / Roger Meissen, University of Missouri Compounds can be 70 times more potent than Tenofovir, a first-line HIV regimen For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the University of Missouri now are testing the next generation of medications that stop HIV from...

2014-02-19 11:04:05

Pittsburgh researchers show how therapy-induced resistance to 'NNRTI' drugs works at 58th Annual Biophysical Society Meeting in San Francisco For the more than one million people with HIV/AIDS in the United States (and the over 34 million people living with HIV/AIDS around the world), antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2013-03-08 00:40:23

Multi-site study, led by a Miriam Hospital researcher, could change treatment strategy for these patients A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression — the primary goal of HIV therapy — without incorporating the traditional class of HIV medications into their treatment regimen. Karen Tashima, M.D., director of the HIV Clinical Trials Program at The Miriam Hospital, served as study chair. The AIDS Clinical Trials Group...

2012-09-13 10:54:04

Doctors can improve treatment programs using this knowledge The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers, including MU scientists, found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regiment they prescribe to HIV-infected individuals. “The...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related